Walking after stem cells in Costa Rica – Video
October 17th, 2011 6:16 amBefore stem cells I had to use furniture and walls to move around. Now it's 1 mounth after treatment - and I'm stille geeting better 🙂
Read the original post:
Before stem cells I had to use furniture and walls to move around. Now it's 1 mounth after treatment - and I'm stille geeting better 🙂
Read the original post:
CosmeticSurg.net | Plastic Surgeons have been performing fat grafting/ fat injections for over a decade. The technique for fat processing has evolved such that properly processed fat is rich in stem cells. Plastic surgeons extract unwanted fat, process it to get the 'good fat' (stem cell...
Go here to read the rest:
Stem Cells from Liposuction Fat: Plastic Surgery's New Frontier - Video
Boston University Professor Dr. George Huang, the Herbert Schilder Chair in Endodontics, Director at Boston University's Henry M
View original post here:
Dr. George Huang joins StemSave. Discusses dental stem cells. - Video
DOWNLOAD HERE: newsdirect.nma.com.tw US scientists have succeeded in producing embryonic stem cells using a new cloning technique. They injected genetic material from a diabetic patient's skin cell into a donor egg, and stimulated it to develop enough so stem cells could be extracted
Visit link:
US scientists unveil new cloning method for embryonic stem cells - Video
Ella Badrudin, a toddler with CP, received umbilical cord stem cells in Hangzhou, China in an effort to improve her condition. In this video her parents talk about the improvements they have seen over their past two visits for treatment.
Read the rest here:
Justin Ichida, Postdoctoral fellow, Eggan laboratory, HSCI. From the SBS Symposium, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine, held in Boston, MA, USA - September 2-3, 2009.
Originally posted here:
Reprogramming Somatic Cells to Pluripotency Using Small Molecules - Video
Hiv Positive Man Cured On the heels of World AIDS Day comes a stunning medical breakthrough: Doctors believe an HIV-positive man who underwent a stem cell transplant has been cured as a result of the procedure. Timothy Ray Brown, also known as the "Berlin Patient," received the transplant in 2007 as part of a lengthy treatment course for leukemia. His doctors recently published a report in the journal Blood affirming that the results of extensive testing "strongly suggest that cure of HIV infection has been achieved." Brown's case paves a path for constructing a permanent cure for HIV through genetically-engineered stem cells.
View original post here:
Regenocyte Therapeutic is the first clinically treating stem cell center based in the United States. Its international team of Board Certified physicians and scientists use adult stem cells taken directly from the patients own blood or bone marrow to treat serious health conditions like congestive heart failure, cardiomyopathy, severe pulmonary diseases, kidney dysfunction, circulation/vascular diseases, dementia, and macular degeneration.
Link:
This is my first day of treatment, my 3rd day in Costa Rica. I had the "mini lipo" this morning, and now I am back at CIMA Hospital to receive my first intrethecal injection of adult stems cells derived from donated umbilical cord blood
See more here:
Learn more about Mayo Clinic's new Regenerative Medicine Consult service from a Mayo Clinic expert on stem cell therapies.
View post:
Amniotic Fluid Based Stem Cell Injections are being offered at Preferred Pain Center in Arizona. The injections offer an opportunity to harness the body's regenerative potential and exponentially increase it: 1) Anti-inflammation 2) Hyaluronic Acid 3) Stem Cells 4) Non-steroidal, non-embryonic treatment Pain relief plus potential regeneration of cartilage and soft tissues such as rotator cuff and ligaments. Now at Preferred Pain Center
Original post:
Regenerative Medicine With Stem Cell Therapy Injections at an Arizona pain clinic (602) 507-6550 - Video
Taking quality multivitamins is a great way to supplement one's diet with high doses of nutrients that are often lacking in modern-day food. And a new study out of Sweden has found that women who take multivitamins help to reduce their overall risk of cardiovascular disease and heart attack.
For ten years, Dr. Susanne Rautiainen and her colleagues from the Karolinska Institutet in Stockholm monitored 31,671 women with no history of heart disease and 2,262 women with heart disease to observe their progression in overall health. Roughly 60 percent of women from both groups took some kind of dietary supplement.
At the completion of the study, 3.4 percent of the women who had no heart disease to begin with, but who did not take any dietary supplements, ended up having heart attacks. In contrast, only 2.6 percent of women from the same group who did take a multivitamin had heart attacks. Statistically, the multivitamin group exhibited a 27 percent less chance of having a heart attack. Read more...
Cardiofy Heart Care Supplement
![]() |
agorafinancial.com | contact us | login
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
International Stem Cell Corporation (OTCBB: ISCO) announces today successful completion of the first series of preclinical studies designed to support the safety and utility of neuronal cells derived from human parthenogenetic stem cell line (hpSC). These initial experiments, demonstrating that the derived neuronal cells were able to survive in mice brains without giving rise to tumors, represent a key milestone towards possible therapeutic applications including treating Parkinson's disease.
Dr. Albrecht Müller, Professor at the Institute of Medical Radiology and Cell Research, Würzburg University (Germany), commented: "Human parthenogenetic stem cells are potentially very promising candidates for use in regenerative medicine primarily because of the possibility that they immune-match a large number of recipients. The result of these safety and survival studies is a very important step along the path towards the clinical use of such cells."
Although most cases of Parkinson's disease occur in people with no family history of the disease, a number of genetic mutations have nevertheless been identified with the disease. While the inheritance pattern is largely unknown, as a condition with a genetic component "autologous" treatment, that is to say treatment using the patient's own cells, is far from ideal and does not offer the potential of a cure. To treat Parkinson's disease successfully a source of cells free of the mutated genes is necessary. Human parthenogenetic stem cells provide this source, as well as superior immune-matching capabilities.
ISCO currently has the world's largest collection of human parthenogenetic stem cells including heterozygous examples, where the cells immune match the donor as is the case with induced pluripotent stem cells (iPS), and homozygous examples which immune-match millions of individuals. ISCO is actively expanding this collection of cell lines and creating a "bank" of homozygous human parthenogenetic stem cells that can be used as a platform to not only reduce the chances of tissue rejection, but also make cellular-based therapies economically more viable.
Dr. Ruslan Semechkin, ISCO's Vice President, commented: "One of ISCO's main therapeutic targets is treatment of Parkinson's disease, a common neurodegenerative disease in the US, where the current standard of care is designed mostly to treat the symptoms, but not the disease. These results clearly represent an important step towards the therapeutic application of human parthenogenetic stem cells derived cells in addressing the basic underlying mechanisms and potentially transforming the treatment of neurodegenerative diseases."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCellTM. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward- looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth C. Aldrich, co -Chairman
760-940-6383
kaldrich@intlstemcell.com
Or:
Dr. Ruslan Semechkin, Vice President
760-940-6383
ras@intlstemcell.com
Or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Taking quality multivitamins is a great way to supplement one's diet with high doses of nutrients that are often lacking in modern-day food. And a new study out of Sweden has found that women who take multivitamins help to reduce their overall risk of cardiovascular disease and heart attack.
For ten years, Dr. Susanne Rautiainen and her colleagues from the Karolinska Institutet in Stockholm monitored 31,671 women with no history of heart disease and 2,262 women with heart disease to observe their progression in overall health. Roughly 60 percent of women from both groups took some kind of dietary supplement.
At the completion of the study, 3.4 percent of the women who had no heart disease to begin with, but who did not take any dietary supplements, ended up having heart attacks. In contrast, only 2.6 percent of women from the same group who did take a multivitamin had heart attacks. Statistically, the multivitamin group exhibited a 27 percent less chance of having a heart attack. Read more...
Cardiofy Heart Care Supplement
![]() |
agorafinancial.com | contact us | login
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
International Stem Cell Corporation (OTCBB: ISCO) announces today successful completion of the first series of preclinical studies designed to support the safety and utility of neuronal cells derived from human parthenogenetic stem cell line (hpSC). These initial experiments, demonstrating that the derived neuronal cells were able to survive in mice brains without giving rise to tumors, represent a key milestone towards possible therapeutic applications including treating Parkinson's disease.
Dr. Albrecht Müller, Professor at the Institute of Medical Radiology and Cell Research, Würzburg University (Germany), commented: "Human parthenogenetic stem cells are potentially very promising candidates for use in regenerative medicine primarily because of the possibility that they immune-match a large number of recipients. The result of these safety and survival studies is a very important step along the path towards the clinical use of such cells."
Although most cases of Parkinson's disease occur in people with no family history of the disease, a number of genetic mutations have nevertheless been identified with the disease. While the inheritance pattern is largely unknown, as a condition with a genetic component "autologous" treatment, that is to say treatment using the patient's own cells, is far from ideal and does not offer the potential of a cure. To treat Parkinson's disease successfully a source of cells free of the mutated genes is necessary. Human parthenogenetic stem cells provide this source, as well as superior immune-matching capabilities.
ISCO currently has the world's largest collection of human parthenogenetic stem cells including heterozygous examples, where the cells immune match the donor as is the case with induced pluripotent stem cells (iPS), and homozygous examples which immune-match millions of individuals. ISCO is actively expanding this collection of cell lines and creating a "bank" of homozygous human parthenogenetic stem cells that can be used as a platform to not only reduce the chances of tissue rejection, but also make cellular-based therapies economically more viable.
Dr. Ruslan Semechkin, ISCO's Vice President, commented: "One of ISCO's main therapeutic targets is treatment of Parkinson's disease, a common neurodegenerative disease in the US, where the current standard of care is designed mostly to treat the symptoms, but not the disease. These results clearly represent an important step towards the therapeutic application of human parthenogenetic stem cells derived cells in addressing the basic underlying mechanisms and potentially transforming the treatment of neurodegenerative diseases."
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCellTM. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com
To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward- looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Kenneth C. Aldrich, co -Chairman
760-940-6383
kaldrich@intlstemcell.com
Or:
Dr. Ruslan Semechkin, Vice President
760-940-6383
ras@intlstemcell.com
Or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss
David Gollaher, president and CEO of California Healthcare Institute, discusses the tensions between stem cell research, ethics, and politics in America that are impeding the progress of developing promising cures.
Read this article:
Life in the Balance: Perspectives on Stem Cell Research - Video